Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy

Summary

A pre-post study will be conducted to assess whether treatment with LXB, nVNS or a combination of both interventions can enhance the clearance of Aβ in patients with CAA. A total of 60 subjects, 30 with sCAA and 30 with D-CAA, will be randomly assigned to receive LXB, or both interventions. The primary outcome measure will be the morning levels of Aβ40 and Aβ42 in cerebrospinal fluid (CSF) before and after the intervention. The investigators will assess disease progression with (non-)haemorrhagic imaging markers on 7-Tesla Magnetic Resonance Imaging (7-T MRI) as a secondary outcome. Additionally, the activity of the glymphatic system by means of fluid dynamics will be assessed using 7-T MRI.

Timeline

Start

2025-03-27

Primary completion

2027-09-27

Completion

2027-09-27

Publications

• Schriemer SE, Hirschler L, van Etten ES, van Zwet EW, Lammers GJ, Liebler EJ, van Walderveen MAA, Slats AM, van Es ACGM, Verbeek MM, van Osch MJP, Wermer MJH, Fronczek R. Stimulating amyloid-beta clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial. BMJ Open. 2026 Mar 11;16(3):e113194. doi: 10.1136/bmjopen-2025-113194.

Drugs

Indications